Sequana Medical AG

• 16.05.2018 – 10:00

  Sequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites

  Zurich (ots) - Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, ...

  mehr

• 19.03.2018 – 10:00

  Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study

  Zurich, SWITZERLAND (ots) - Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of ...

  mehr

• 24.10.2017 – 10:00

  Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD

  Zurich (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, presented the findings of the MOSAIC study data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The ...

  mehr

• 19.10.2017 – 10:00

  Sequana Medical Announces 2017 AASLD Poster Presentation

  Zurich (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that it will have a poster presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), being held October 20-24 in Washington, DC. Dr. Gijs Klarenbeek,MD, Chief Medical ...

  mehr

• 04.10.2017 – 10:00

  Sequana Medical Announces Publication of Results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T)

  Zurich, Switzerland (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis", the results of the first ...

  mehr

• 06.07.2017 – 09:30

  Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study for the alfapump® vs. Large Volume Paracentesis for Refractory Ascites in Journal of Hepatology

  Zurich (ots) - Sequana Medical AG ("Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology (http://ots.ch/w2er5). The study demonstrated that in patients with ...

  mehr

• 30.10.2012 – 12:00

  Sequana Medical receives CE-mark approval for the use of its alfapump® system in cancer patients with malignant ascites

  Zurich, Switzerland (ots) - Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites ...

  mehr

• 01.03.2012 – 07:00

  Sequana Medical's ALFApump® System receives reimbursement in Germany for breakthrough technology in ascites management

  Zurich (ots) - NUB grants approval for fifteen leading hepatology centres in Germany. Sequana Medical announced today that its ALFApump® System has received German Neue Untersuchungs und Behandlungsmethode (NUB) approval which allows participating hospitals to receive reimbursement for innovative new products. ...

  mehr

• 09.12.2011 – 07:00

  NHS National Innovation Centre estimates Sequana Medical's ALFApump® System could save the NHS £50 million in ascites care annually

  Zurich, Switzerland (ots) - NHS National Innovation Centre supports the cost effectiveness of Sequana Medical's ALFApump System Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System commissioned by the National Innovation Centre, the NHS organization which supports ...

  mehr

• 04.11.2011 – 11:23

  The Medical University of Vienna and Vienna General Hospital perform the first two commercial implants worldwide of Sequana Medical's ALFApump® System

  Zurich (ots) - Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis. Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ...

  mehr

• 13.07.2011 – 07:00

  Sequana Medical receives CE Mark Approval for the ALFApump System and adds Key Executive to Team

  Zurich, Switzerland (ots) - New technology expands treatment options for patient with refractory ascites due to liver cirrhosis. Dr. Farzana Malik joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System. Over the coming months, the company will ...

  mehr